Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients?
Alessandra Fabi(Agostino Gemelli University Polyclinic), F. Cognetti(Sapienza University of Rome), Nello Salesi(Tumori Foundation), Fabiana Letizia Cecere, Barbara Di Cocco(Tumori Foundation), G. Ferretti(Istituti di Ricovero e Cura a Carattere Scientifico), C. Nardoni(Cancer Institute (WIA)), Paola Papaldo(Cancer Institute (WIA)), Paolo Carlini(National Cancer Institute), Mariangela Ciccarese, Alessandra Felici
Cited by 4
Related Papers
CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
|Journal of Clinical Oncology|2015|253
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
|The Lancet|2015|202
Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. Italian Multicentre Breast Study with Epirubicin.
|Journal of Clinical Oncology|1988|168
Lonidamine: Efficacy and safety in clinical trials for thetreatment of solid tumors
|Drugs of today|2003|168